Moderna says that its mRNA flu shot, mRNA-1010, is one step closer to making it across the finish line.
As a part of the company’s annual R&D day, Moderna revealed development and business updates which included news on the latest data from mRNA-1010’s phase 3 trial. An interim analysis of the trial, P303, revealed that the vaccine met all of its endpoints, and provided improved immunogenicity for all four A and B strains (A/H1N1, A/H3N2, influenza B/Yamagata, B/Victoria).
The jab also showed effectiveness across all age groups and older adults. According to Moderna, mRNA-1010 elicited a stronger immune response when compared to GSK’s approved quadrivalent shot, Fluarix.
The drugmaker says consultations with regulators on a potential licensing package for the vaccine are currently ongoing based on the data.
Other companies, such as Pfizer have been pursuing their own mRNA flu shots. Last September, Pfizer shared its own phase 2 results from its jab, saying that mRNA vaccines offer advantages over conventional jabs include such as an improved strain match, more rapid and reliable manufacturing to facilitate seasonal strain changes, and broader immune responses in patients.